• 7-dehydro Cholesterol and Causal Inference

  2026-10-09

  7-dehydro Cholesterol is more than a vitamin D3 precursor: it is a useful lens for interpreting DHCR7, sterol flux, oxidative stress, and immune phenotypes. This article examines what recent grass carp evidence establishes, what it does not prove, and how C3922 can support cross-disciplinary research without overstating causality.

• Lenalidomide (CC-5013): Evidence and Mechanism

  2026-10-09

  Lenalidomide, also called CC-5013, is an immunomodulatory drug studied in multiple myeloma and other hematologic malignancies. Recent evidence indicates that DOT1L inhibition can enhance lenalidomide-associated anti-myeloma activity through innate immune signaling, but the finding remains preclinical and model-dependent.

• Isoprinosine: Evidence, Mechanisms, and Limits

  2026-10-08

  Isoprinosine, or inosine pranobex, is described as an immunomodulatory agent for viral infections, but the supplied evidence varies substantially in provenance and detail. This overview separates supplier-reported claims from findings in a 2024 herpesvirus preprint, explains why CLCC1 biology does not establish an Isoprinosine mechanism, and outlines research applications, evidence gaps, and applicability boundaries.

• In Vitro Drug Response Analysis in Cancer

  2026-10-08

  Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability measure related but distinct components of anticancer drug response. Its central contribution is a framework for separating growth inhibition from cell killing, improving interpretation of in vitro studies without treating a single viability value as a complete mechanistic explanation.

• DOT1L, STING, and Lenalidomide in Myeloma

  2026-10-07

  A 2025 Cancer Letters study identifies DOT1L as a preferential epigenetic dependency in multiple myeloma and links its inhibition to DNA damage-associated STING signaling, type I interferon responses, and HLA class II induction. The findings provide a mechanistic rationale for combining DOT1L inhibition with lenalidomide, while remaining preclinical and requiring validation beyond the reported models.

• Ridaforolimus and Senescence Research: Evidence Review

  2026-10-07

  Ridaforolimus, also called Deforolimus or MK-8669, is a research compound described as a selective mTOR inhibitor with reported antiproliferative and anti-angiogenic activity. This overview compares those supplier-reported findings with the published machine-learning senolytic study by Smer-Barreto and colleagues, emphasizing what is established, what remains hypothetical, and where the evidence cannot support broader conclusions.

• EGCG Nanoparticles Enhance FLASH-RT Antitumor Effects

  2026-10-06

  Xu et al. report that functionalized, self-assembled epigallocatechin gallate nanoparticles, termed BENPs, can increase tumor-cell damage and immune activation during FLASH radiotherapy in preclinical models. The study is notable because it addresses the efficacy gap in FLASH-RT through biochemical radiosensitization, while its findings remain limited by model scope, short-term safety measures, and the absence of clinical validation.

• Ibrexafungerp: From Mechanism to Translation

  2026-10-06

  Ibrexafungerp, also known as MK 3118, illustrates how mechanism, environmental context, and resistance biology can be integrated into a translational antifungal strategy. Evidence from Candida isolates supports activity in acidic conditions, while important boundaries remain between in vitro susceptibility, animal models, and clinical decision-making.

• Masitinib (AB1010): Product Overview

  2026-10-05

  Masitinib (AB1010), SKU A2942, is a supplier-described phenylaminothiazole-type tyrosine kinase inhibitor associated with KIT, PDGFRα, PDGFRβ, mast-cell biology, and cancer research. No matched paper evidence was available for this overview.

• Acetylation Biomarkers in Osteoarthritis: Study Analysis

  2026-10-05

  Li et al. integrate transcriptomic datasets, co-expression analysis, machine learning, immune-infiltration estimates, and molecular validation to identify JUN and MYC as acetylation-related osteoarthritis biomarkers. The findings are promising for hypothesis generation, but the diagnostic model and mechanistic interpretation require broader external and functional validation.

• Lenalidomide and the Epigenetic Logic of Myeloma

  2026-10-04

  Lenalidomide research is moving beyond broad immunomodulation toward biomarker-led combinations. New findings connect DOT1L inhibition, innate immune signaling, and IRF4-MYC suppression, creating a translational framework for evaluating CC-5013 in multiple myeloma research.

• Radicicol: Five Questions on Evidence and Scope

  2026-10-03

  A source-grounded overview of Radicicol as an Hsp90 inhibitor, separating reported mechanisms from interpretation and clarifying what current evidence can—and cannot—support across cancer, adipocyte, inflammation and vaccine research.

• Concanavalin A and Conserved Coronavirus Glycans

  2026-10-02

  Guo and colleagues identify conserved high-mannose N-glycosylation sites near the coronavirus spike S2′ cleavage site as a broad antiviral vulnerability. By combining fusion, pseudovirus, authentic-virus, biochemical, and animal models, the study shows that concanavalin A can obstruct spike activation and reduce hCoV-NL63 disease in vivo.

• CD40–STING–TRAF2 Axis in ESCC B Cells

  2026-10-01

  A 2025 study links tertiary lymphoid structures with favorable survival in treatment-naïve esophageal squamous cell carcinoma and identifies IRF4-high B cells as a central immune feature. Its mechanistic experiments indicate that CD40 and STING compete for TRAF2, shaping non-canonical NF-κB signaling and IRF4-mediated B-cell activation.

• Sulfur Supply Delays Soybean Nodule Senescence

  2026-10-01

  The reference study identifies sulfur delivery into the soybean symbiosome as a regulatory checkpoint that preserves glutathione-dependent scavenging of reactive nitrogen species and delays nodule senescence. Its genetic, mineral-transport, and biochemical evidence connects SULTR-mediated sulfur supply with sustained symbiotic nitrogen fixation and suggests measurable targets for future nodule stress research.

8495 records 1/567 page Next 12345 下5页 Last page